A method for providing a two stage diet for an Ulcerative Colitis patient, and therapeutic meals for same, the method comprising stage 1 which is provided in weeks 0-6, and stage 2 which is provided in weeks 7-12; the diet described herein providing dietary components with reduced content of animal fat, dairy products, gluten, taurine, yeast, sulfites, and emsulsifiers.

A method for providing a two stage diet for an Ulcerative Colitis patient, and therapeutic meals for same, the method comprising stage 1 which is provided in weeks 0-6, and stage 2 which is provided in weeks 7-12; the diet described herein providing dietary components with reduced content of animal fat, dairy products, gluten, taurine, yeast, sulfites, and emsulsifiers.

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.

A topical formulation comprising a Cannabis derived botanical drug product, wherein the concentration of each, cannabidiol and tetrahydrocannabinol, in the topical formulation is greater than 2 milligrams per kilogram.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which •modities low-threshold or transient neuronal calcium currents, or •reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

Compositions and methods of manufacturing mineral pitch resin compositions comprising at least one of a cannabinoid, a terpene, a terpenoid, an essential oil and a fatty acid are provided. Such mineral pitch resin compositions may be safely consumed orally, topically or otherwise, and have numerous health benefits.

The invention relates to the use of various extracts of the Nephelium lappaceum plant for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I and/or type V collagen and/or LOX-L, fibulin-5, emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and mucous membranes. Another subject of the invention relates to the use of said extracts in a cosmetic composition comprising at least one cosmetically acceptable excipient. Another subject further relates to a cosmetic care method comprising the application of the extract according to the invention or of a cosmetic composition comprising it, for increasing the firmness and/or elasticity of the skin and/or mucous membranes, by increasing type I and/or type V collagen, fibrillin-1 and/or LOX-L, fibulin-5, emiline-1 and/or fibrillin-1 gene and/or protein expression, and/or by decreasing CYR61 expression, in the skin and mucous membranes. A final subject relates to an N. lappaceum extract for use thereof, alone or in a dermatological or pharmaceutical composition, in the prevention and/or treatment of pathological conditions involving a loss of collagen protein and/or gene expression and/or a pathological loss of firmness of the skin and/or mucus membranes, such as rosacea and telangiectasia.